Detalhe da pesquisa
1.
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
N Engl J Med
; 390(8): 723-735, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38381675
2.
Moving toward disease modification in polycythemia vera.
Blood
; 142(22): 1859-1870, 2023 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37729609
3.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441846
4.
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Blood
; 142(12): 1056-1070, 2023 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37339579
5.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Blood
; 141(6): 567-578, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399715
6.
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Lancet Oncol
; 25(3): 388-399, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423051
7.
Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
Cancer
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620053
8.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer
; 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591430
9.
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol
; 204(3): 898-909, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946611
10.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361282
11.
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting.
Oncology (Williston Park)
; 38(3): 104-106, 2024 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517410
12.
The role of therapy in the outcome of patients with myelofibrosis.
Cancer
; 129(18): 2828-2835, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243913
13.
New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-XL /BCL-2 inhibition with navitoclax.
Cancer
; 129(22): 3535-3545, 2023 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584267
14.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
15.
Association between bariatric surgery and outcomes in chronic myeloid leukemia.
Cancer
; 129(12): 1866-1872, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36882573
16.
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Br J Haematol
; 203(4): 581-592, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608562
17.
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia.
Blood
; 138(18): 1733-1739, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34115096
18.
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Haematologica
; 108(10): 2626-2638, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078252
19.
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
Haematologica
; 108(9): 2331-2342, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951163
20.
Real-world treatments and thrombotic events in polycythemia vera patients in the USA.
Ann Hematol
; 102(3): 571-581, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36637474